Contract Research Organizations (CROs) offer end-to-end solutions in conducting clinical trials for pharmaceutical, biotechnology and medical device companies, collectively referred to as sponsors.
The global CRO market was valued at $44.4 billion in 2017.
North America was the largest region in the global CRO market accounting for less than 45% share of the market. The USA was the largest country in the global CRO market, with around 33% share of the market.
Major trends shaping the CRO market include increasing focus on emerging markets, real world evidence in clinical trials, strategic partnerships to benefit cros and sponsors alike, adaptive trial design, increase in M&A activity, growing investments in technology, and personalized medicine/genetic testing capabilities.
The top 5 companies covered are IQVIA, PPD (Private), Syneos Health, PAREXEL and PRA Health Sciences.
IQVIA was the largest company in the market.
The countries covered are USA, Japan, Germany, France, Australia, Brazil, Italy, China, Russia, Spain, UK, India and others.
CRO market is segmented on the basis of type of services provided as follows –
Drug Discovery – The goal of the drug discovery process is to find a promising molecule or lead compound, from a pool of 10,000-15,000 compounds that has the potential to become a new medicine.
Preclinical Studies – In this stage, the relevant compounds are tested in-vitro (in tubes) and in-vivo (animals) over a wide range of doses to establish relative toxicity of the compound and detect any potential adverse reactions to the therapeutic.
Phase I – During the earliest phase of clinical (human) trials, testing is focused on basic safety and pharmacology.
Phase II – In this phase, the primary focus is on efficacy evaluation, along with determination of optimal dosage levels, dosage schedule and administration routes.
Phase III – In this phase, advanced efficacy and safety testing is completed to provide enough data for valid statistical conclusions required by the regulatory authority.
Phase IV – Phase IV research takes place after the regulatory body approves the marketing of a new drug. Through Phase IV clinical studies, new drugs are tested continuously to uncover more information about efficacy, safety and side effects after being approved for marketing.
Other Services – The Others segment includes various support activities such as pharmacovigilance, bio-statistics, clinical data management, site management, monitoring, regulatory services, protocol development and medical writing.
The CRO market is also segmented on the basis of therapeutic areas as follows –
• Infectious Diseases
• Central Nervous System
• Cardiovascular Diseases
• Metabolic Diseases
• Other Therapeutic Areas